Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
Content archived on 2024-06-25

Mucosal Vaccines for Poverty Related Diseases

Objective

The project is focused on the development of mucosal vaccines against AIDS and tuberculosis (TB) and is based on the use of antigens validated as safe and effective in animal models. Mucosal vaccines present advantages of practical and social relevance when compared to parenteral. To ensure vaccine compliance, accessibility, and coverage, vaccines should be designed which can be administered by convenient mucosal routes of delivery. Mucosal vaccines, inducing both local and systematic immune responses, are considered moreeffective in controlling mucosally-acquired infections, such as HIV and TB.

The project consists of two major parallel interlinked tracks: i) phase I trials of mucosal immunization using antigens and adjuvants validated in previous preclinical and clinical studies ii) development of new candidate vaccines for mucosal immunization and their comparative selection in animal models. Antigens such as GAg, V2-deleted gp 120, Tat (HIV-1), and Ag85B/ESAT-6 hybrid molecule (TB), and adjuvants such as LTK63 and HSP70, will be used in combination for phase I trials to be performed first in Europe and than in Africa Development of new vaccine candidates will not include antigen discovery but would rather be based on the novel use of adjuvants and delivery systems in combination with promising antigens. Animal models of increasing relevance for human vaccines will be used to compare new candidates and to select those which should proceed to phase I trials.

The final expected result of this Project is to provide candidate mucosal vaccines, with proved safety and immunogenicity in humans, that could subsequently enter the path towards licensure through phase II and III clinical trials. The European Developing Countries Clinical Trials Partnership which is expected to be soon operative could be instrumental in exploiting the results obtained in this project by testing mucosalvaccines against these devasting diseases in developing countries.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP6-2002-LIFESCIHEALTH
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

IP - Integrated Project

Coordinator

NOVARTIS VACCINES AND DIAGNOSTICS SRL
EU contribution
No data
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (29)

My booklet 0 0